HealthTell, Inc. Launches New Pre-Clinical Services Business

SAN RAMON, Calif., May 2, 2017 /PRNewswire/ -- HealthTell today announced it will be launching a new business segment to service the pre-clinical drug discovery market. Preview into HealthTell's capabilities will be featured at the 13^th Annual Protein Engineering Summit (PEGS) at the Seasport World Trade Center in Boston, May 1-5^th. 

Poster Presentations

Title: High-Throughput, Information-Rich Antibody Characterization Across Diverse Sequence-Space
Presenter: Matthew Greving, PhD
Date: Monday - Tuesday, May 1-2, 2017

Title:  Antibody Specificity Measurement by Exploration of Diverse Sequence-Space
Presenter: Ted Tarasow, PhD
Date: Monday - Tuesday, May 1-2, 2017

"We are excited about HealthTell's platform to significantly improve the quality of therapeutic antibody candidates in the process of drug discovery. We substantially enrich antibody binding information for our customers, and we have the capability to improve the selection of antibody candidates identified in the drug discovery process. This includes improved resolution of epitope binning, off-target binding, linear/structural epitope mapping, and key residue contributions," said Bill Colston, CEO.

HealthTell has applied their high-density array-based peptide library platform to characterize antibody (Ab, mAb) binding profiles and address key limitations of current approaches. Specifically: 1) Assays are performed in high-throughput 96-well microtiter format, 2) Low-cost, comprehensive and position-level mAb binding sequence space coverage is achieved with a 126K diverse sequence peptide array library to drive the design of a 17K focused sequence peptide array library,  and 3) These arrays do not require prior epitope knowledge for library design, binding profile measurement and epitope identification.

About HealthTell, Inc.

HealthTell, Inc (http://www.HealthTell.com), headquartered in San Ramon, CA, is pioneering the field of immunomics. The company is developing next generation immune profiling assays that broadly characterize the immune system, serving as a platform technology for the biopharmaceutical, search and clinical communities. The technology uses a proprietary immune profiling technology to analyze the immune system's response against disease – with unprecedented depth and specificity. With applications in drug target discovery, monoclonal antibody characterization, and disease monitoring and therapeutic response, HealthTell will shed new light on important diseases such as autoimmune, cancer, CNS, and infectious disease. HealthTell operates a state-of-the-art high throughput centralized laboratory in San Ramon, CA that supports clients in biopharmaceuticals, and research collaborators.

SOURCE HealthTell, Inc.

Related Links

http://www.HealthTell.com